This Article Full Text Full Text (PDF) CME: Take the course for this article: Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fiorica, J. V. Search for Related Content PubMed PubMed Citation Articles by Fiorica, J. V.

Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA

Correspondence: James V. Fiorica, M.D., H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612-9497, USA. Telephone: 813-972-8478; Fax: 813-903-3538; e-mail: fiorica{at}moffitt.usf.edu

Carcinomas of the uterine cervix and corpus are significant causes of morbidity and mortality among women in the U.S. and are expected to contribute 10,700 deaths in 2002. Despite the widespread use of cytologic screening and improvements in early diagnosis, mortality rates have changed little over the past 25 years, and the management of cervical and uterine cancers remains a significant unmet medical need. Currently available modalities, including radiotherapy and cisplatin-based chemotherapy, provide suboptimal control of disease, and there are no effective treatments for recurrent disease. The antitumor activity and tolerability of a number of novel agents, including topoisomerase I inhibitors, vinca alkaloids, taxanes, and gemcitabine, have been of considerable interest in treatment of these cancers. This review discusses current trends in the treatment of cervical and endometrial carcinomas, focusing on the potential role of topotecan in the treatment of non-ovarian gynecologic malignancies.

Key Words. Cervical neoplasms • Cisplatin • Radiotherapy • Topotecan • Uterine neoplasms

This article has been cited by other articles:

				A. Rossi, S. Ciafre, M. Balsamo, P. Pierimarchi, and M. G. Santoro Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res., August 1, 2006; 66(15): 7678 - 7685. [Abstract] [Full Text] [PDF]

				R. C. A. M. van Waardenburg, L. A. de Jong, M. A. J. van Eijndhoven, C. Verseyden, D. Pluim, L. E. T. Jansen, M.-A. Bjornsti, and J. H. M. Schellens Platinated DNA Adducts Enhance Poisoning of DNA Topoisomerase I by Camptothecin J. Biol. Chem., December 24, 2004; 279(52): 54502 - 54509. [Abstract] [Full Text] [PDF]